July 5, 2019
Ipsen, Servier kick off Phase 1/2 testing Liposomal Irinotecanas as treatment for Metastatic Pancreatic Cancer
Treatment emergent adverse events Grade 3 or higher were reported by 20 of 32 patients from the 50/60 dose pooled patient analysis; no patient reported Grade 3 or higher fatigue or peripheral neuropathy (primary endpoint) –